Kiromic BioPharma, Inc. (KRBP) |
|
4.11 0.18 (4.58%)
|
03-24 15:59 |
|
Open: |
3.95 |
Pre. Close: |
3.93 |
|
High:
|
4.1599 |
Low:
|
3.95 |
|
Volume:
|
10,390 |
Market Cap:
|
3(M) |
|
|
|
Technical analysis |
as of: 2023-03-24 4:27:33 PM |
|
Overall:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
| Target: |
Six months: 7.63 One year: 8.92 |
| Support: |
Support1: 2.58 Support2: 0.13 |
| Resistance: |
Resistance1: 6.53 Resistance2: 7.63 |
| Pivot: |
2.91  |
| Moving Average: |
MA(5): 4.14  MA(20): 2.22
MA(100): 0.62 MA(250): 0.51 |
| MACD: |
MACD(12,26): 1 Signal(9): 0.9 |
| Stochastic oscillator: |
%K(14,3): 61.7 %D(3): 62.6 |
| RSI: |
RSI(14): 73.6 |
| 52-week: |
High: 6.53 Low: 0.13 |
| Average Vol(K): |
3-Month: 2,112 (K) 10-Days: 174 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ KRBP ] has closed below upper band by 34.7%. Bollinger Bands are 874.2% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 9 days. This is a sign that the current trend might continue. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
4.17 - 4.19 |
4.19 - 4.21 |
|
Low:
|
3.89 - 3.92 |
3.92 - 3.95 |
|
Close:
|
4.07 - 4.11 |
4.11 - 4.15 |
|
Company Description |
|
Kiromic BioPharma, Inc., an artificial intelligence driven allogeneic cell therapy company, engages in developing the multi-indication allogeneic T cell therapies that exploits the natural potency of the Gamma Delta T cell to target solid tumors. The company develops ALEXIS-ISO-1, an allogenic gamma delta CAR-T cell therapy product candidate targeting Isomesothelin; and ALEXIS-PRO-1, an allogeneic gamma delta chimeric T cell therapy product candidate targeting PD-L1. It has license agreements with CGA 369 Intellectual Holdings, Inc. and Longwood University, as well as a research and development collaboration agreement with Molipharma, S.R.L. The company also has strategic alliance agreement with Leon Office (H.K.) Ltd. The company was formerly known as Kiromic, Inc. and changed its name to Kiromic BioPharma, Inc. in December 2019. Kiromic BioPharma, Inc. was founded in 2006 and is headquartered in Houston, Texas. |
Headline News |
Fri, 17 Mar 2023
Will Kiromic Biopharma Inc (KRBP) Stay at the Bottom of the Healthcare Sector? - InvestorsObserver
Wed, 15 Mar 2023
Healthcare Stocks on the Move Wednesday: THMO, MLEC, ELEV, JNCE, EUDA, SY, KRBP, ONCS - InvestorsObserver
Thu, 09 Mar 2023
What is the Market's View on Kiromic Biopharma Inc (KRBP) Stock's Price and Volume Trends Thursday? - InvestorsObserver
Thu, 09 Mar 2023
Why Cassava Sciences Shares Are Trading Higher By 12%; Here ... - Investing.com UK
Thu, 09 Mar 2023
Nano Caps With Big Breakout Potential (EPAZ, HNRC, KRBP, NLTX) - Marketscreener.com
Tue, 28 Feb 2023
Is Kiromic Biopharma Inc (KRBP) Stock a Good Value? - InvestorsObserver
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Neutral |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
21 (M) |
| Shares Float |
15 (M) |
|
% Held by Insiders
|
5.8 (%) |
|
% Held by Institutions
|
15.6 (%) |
|
Shares Short
|
332 (K) |
|
Shares Short P.Month
|
218 (K) |
Stock Financials |
|
EPS
|
-2.25 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0.66 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
-82.9 |
|
Return on Equity (ttm)
|
-202.7 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
-1.62 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-29 (M) |
|
Levered Free Cash Flow
|
-17 (M) |
Stock Valuations |
|
PE Ratio
|
-1.84 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
6.22 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-2.93 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
